natgillin/translations-raw huggingface dataset:
I AS-studie 1 og -studie 2 viste patienter, der blev behandlet med Cosentyx 150 mg, forbedringer i helbredsrelateret livskvalitet målt ved ASQoL (p=0,001) og SF-36 Physical Component Summary (SF- 36 PCS) (p<0,001).
In AS Study 1 and Study 2, patients treated with Cosentyx 150 mg showed improvements in health- related quality of life as measured by AS Quality of Life Questionnaire (ASQoL) (p=0.001) and SF-36 Physical Component Summary (SF-36PCS) (p<0.001).
I AS-studie 2 medførte behandling med Cosentyx 150 mg en større forbedring i målene for sygdomsaktivitet sammenlignet med placebo ved uge 16 (se tabel 7).
In AS Study 2, treatment with Cosentyx 150 mg resulted in greater improvement in measures of disease activity compared with placebo at Week 16 (see Table 7).
I ASPIRE havde mere end 90 % af patienterne mindst to bedømmelsesvæ rdige røntgenbilleder.
In ASPIRE, more than 90% of patients had at least two evaluable X-rays.
I ASSERT sås forbedring af tegn og symptomer så tidliget som i uge 2.
In ASSERT, improvement in signs and symptoms was observed as early as week 2.
I BALLR1-forsøget, hvor effekterne af iNO til for tidligt fødte børn ligeledes blev undersøgt, men hvor iNO blev iværksat efter 7 dage og i en dosis på 20 ppm, blev der konstateret en signifikant stigning i antal spædbørn, der var i live uden BPD ved gestationsuge 36, 121 (45 % vs.
The BALLR1 study, also evaluating the effects of iNO in preterm neonates, but initiating iNO at 7 days and in a dose of 20 ppm, found a significant increase in neonates alive without BPD at gestational week 36, 121 (45 % vs.
I BCIRG 006-studiet blev Herceptin administreret enten i kombination med docetaxel efter AC- kemoterapi (AC→DH) eller i kombination med docetaxel og carboplatin (DCarbH).
In the BCIRG 006 study Herceptin was administered either in combination with docetaxel, following AC chemotherapy (AC→DH) or in combination with docetaxel and carboplatin (DCarbH).
I BCIRG 006-studiet havde 213/1.075 patienter i DCarbH (TCH)-armen, 221/1.074 patienter i AC→DH (AC→TH)-armen og 217/1.073 patienter i AC→D (AC→T)-armen en Karnofsky performance status ≤ 90 (enten 80 eller 90).
In study BCIRG 006, 213/1075 patients in the DCarbH (TCH) arm, 221/1074 patients in the ACDH (ACTH) arm, and 217/1073 in the AC→D (ACT) arm had a Karnofsky performance status ≤90 (either 80 or 90).
I BCIRG 006-studiet var HER2-positiv tidlig brystkræft defineret som brystkræft hos enten patienter med positive lymfeknuder eller hos højrisiko-patienter med negative lymfeknuder, hvor ingen (pN0) lymfeknude var involveret og mindst 1 af følgende faktorer: tumorstørrelse større end 2 cm, østrogenreceptor- og progesteronreceptor-negative, histologisk og/eller kernegrad 2-3 eller alder < 35 år).
In the BCIRG 006 study HER2 positive, EBC was defined as either lymph node positive or high risk node negative patients with no (pN0) lymph node involvement, and at least 1 of the following factors: tumour size greater than 2 cm, estrogen receptor and progesterone receptor negative, histological and/or nuclear grade 2-3, or age < 35 years.
I begge arme anvendes et optimeret baggrundsregime (OBR) med ≥ 2 NRTI’er.
Both arms used an optimised background regimen (OBR) of ≥ 2 NRTIs.
I begge arme blev dosis titreret to gange om ugen i overensstemmelse med tabel 2.
The dose in both arms was titrated twice weekly according to Table 2.
I begge AS-studier udviste patienter behandlet med Cosentyx (150 mg i AS-studie 2 og begge regimer i AS-studie 1) signifikante forbedringer i tegn og symptomer ved uge 16, og respons og effekt i sammenlignelig størrelsesorden blev opretholdt til uge 52 hos både anti-TNFα-naive og anti-TNFα-IR-patienter.
In both AS studies, Cosentyx-treated patients (150 mg in AS Study 2 and both regimens in AS Study 1) demonstrated significantly improved signs and symptoms at Week 16, with comparable magnitude of response and efficacy maintained up to Week 52 in both anti-TNFα-naive and anti-TNFα-IR patients.
I begge behandlingsarme havde børn i alderen 6 til 11 år en numerisk højere hyppighed af bekræftet natlig hypoglykæmi end de andre aldersgrupper.
In both treatment arms, children aged 6-11 years had a numercally higher rate of confirmed hypoglycaemia than in the other age groups.
I begge behandlingsarme havde cirrosepatienter højere risiko for at opleve grad 3-4 trombocytopeni sammenlignet med patienter, som ikke havde cirrose.
In both treatment arms, patients with cirrhosis were at a higher risk to experience Grade 3-4 thrombocytopenia compared with non cirrhotic patients.
I begge behandlingsgrupper med edoxaban fik personerne deres dosis halveret, hvis en eller flere af følgende kliniske faktorer var til stede: moderat nedsat nyrefunktion (CrCl 30 – 50 ml/min), lav legemsvægt ( 60 kg) eller samtidig anvendelse af specifikke P-gp-hæmmere (verapamil, quinidin, dronedaron).
Subjects in both edoxaban treatment groups had their dose halved if one or more of the following clinical factors were present: moderate renal impairment (CrCL 30 – 50 mL/min), low body weight ( 60 kg) or concomitant use of specific P-gp inhibitors (verapamil, quinidine, dronedarone).
I begge behandlingsgrupper stod ekkymoser eller gastro- intestinale blødninger for de fleste blødningstilfælde.
In both treatment groups, the majority of bleeding events were ecchymosis or gastrointestinal tract bleeding.
I begge de dobbeltblinde, randomiserede, vehikel-kontrollerede studier, der blev udført hos diabetespatienter med retinopati, udviklede en signifikant højere procentdel af patienterne i vehikel- gruppen makulært ødem (17,3 % og 14,3 %) sammenlignet med de patienter, der blev behandlet med Nevanac 3 mg/ml (2,3 % og 5,9 %).
In both double-masked, randomised vehicle-controlled studies, conducted in diabetic retinopathy patients, a significantly greater percentage of patients in the vehicle group developed macular oedema (17.3% and 14.3%) compared to patients treated with NEVANAC 3 mg/ml (2.3% and 5.9%).
I begge INPULSIS-studier var risikoen for progression statistisk signifikant reduceret hos patienter, der blev behandlet med nintedanib, i forhold til placebogruppen.
In both INPULSIS trials, the risk of progression was statistically significantly reduced for patients treated with nintedanib compared with placebo.
I begge kliniske studier fik patienter i kontrolarmen placebo, og det var tilladt, men ikke påkrævet, at patienterne fik prednison (maksimal daglig tilladte dosis var 10 mg prednison eller ækvivalent).
In both clinical trials, patients received placebo in the control arm and patients were allowed, but not required, to take prednisone (maximum daily dose allowed was 10 mg prednisone or equivalent).
I begge kohorter udviste forsøgspersoner, der blev behandlet med vareniclin, statistisk superioritet ift.
In both cohorts, subjects treated with varenicline demonstrated statistical superiority of
I begge studiearme blev behandlingen administreret indtil sygdomsprogression eller udvikling af uacceptabel toksicitet.
both study arms treatment was administered until disease progression or development of an unacceptable toxicity.
I begge studier anvendtes et OBR, der bestod af mindst 2 NRTI’er med eller uden enfuvirtid (ENF).
An OBR consisting of at least 2 NRTIs with or without enfuvirtide (ENF) was used in both trials.
I begge studier blev ambrisentan tilføjet til patienternes støttende/bagvedliggende behandling, som kunne omfatte en kombination af digoxin, antikoagulantia, diuretika, oxygen og vasodilatatorer (kalciumkanalblokkere, ACE-hæmmere).
In both studies, ambrisentan was added to patients’ supportive/background medication, which could have included a combination of digoxin, anticoagulants, diuretics, oxygen and vasodilators (calcium channel blockers, ACE inhibitors).
I begge studier blev baseline-demografiske og sygdomsrelaterede karakteristika sammenlignet mellem lenalidomid/dexamethason-og placebo/dexamethason-grupperne.
In both studies, the baseline demographic and disease-related characteristics were comparable between the lenalidomide/dexamethasone and placebo/dexamethasone groups.
I begge studier blev det maksimale middelniveau af FPG og HbA1c nået inden for de første tre måneders behandling med pasireotid til intramuskulær anvendelse.
In both studies, mean FPG and HbA1c levels peaked within the first three months of treatment with pasireotide intramuscular use.
I begge studier blev en astmaeksacerbation defineret som en forværring af astma, der krævede følgende medicinsk intervention: anvendelse af systemisk kortikosteroid eller en øget anvendelse af ICS i 3 eller flere dage, og/eller astmarelateret akutbehandling, herunder mindst ét af følgende: et ikke planlagt besøg hos læge eller sundhedsperson for behandling med nebulisator eller anden akutbehandling for at hindre forværring af astmasymptomer; besøg på skadestue for astmarelateret behandling eller astmarelateret indlæggelse.
In both studies, an asthma exacerbation was defined as a worsening of asthma that required the following medical intervention: use of systemic corticosteroids or an increase in the use of ICS treatment for 3 or more days, and/or asthma-related emergency treatment including at least one of the following: an unscheduled visit to their healthcare professional for nebuliser treatment or other urgent treatment to prevent worsening of asthma symptoms; a visit to the emergency room for asthma-related treatment; or asthma-related hospitalisation.
I begge studier blev patienterne i forholdet 1:1:1 tilfældigt tildelt ét ud af tre doseringsskemaer:
In both studies, patients were randomly assigned in a 1:1:1 ratio to 1 of 3 dosing regimens:
I begge studier blev patienterne stratificeret efter baseline hiv 1-rna (≤ 100.000 kopier/ml, > 100.000 kopier/ml til
In both studies, patients were stratified by baseline HIV-1 RNA (≤ 100,000 copies/mL, > 100,000 copies/mL to
I begge studier blev patienterne stratificeret ved baseline hiv 1-rna (≤ 100.000 kopier/ml, > 100.000 kopier/ml til
In both studies, patients were stratified by baseline HIV-1 RNA (≤ 100,000 copies/mL, > 100,000 copies/mL to
I begge studier fik patienterne et doseringsregime med 0,5 mg ranibizumab efter behov (p.n.) drevet af individuaelle stabilisationskriterier.
In both studies, subjects received a 0.5 mg ranibizumab PRN dosing regimen driven by individualised stabilisation criteria.
I begge studier fik personerne enten et 2-dosisprogram med Ambirix eller et 3-dosisprogram med den kombinerede vaccine indeholdende 360 ELISA-enheder formalininaktiveret hepatitis A-virus og 10 mikrogram rekombinant hepatitis B- overfladeantigen.
In both studies, subjects received either a two dose schedule of Ambirix or a three dose regimen of the combined vaccine containing 360 ELISA Units of formalin inactivated hepatitis A virus and 10 micrograms of recombinant hepatitis B surface antigen.
I begge studier forblev den gennemsnitlige procentvise forbedring i PASI fra baseline stabil under den randomiserede seponeringsfase af behandlingen for patienter, der blev randomiseret igen til apremilast efter uge 32 (tabel 5).
In both studies, the mean percent improvement in PASI from baseline remained stable during the Randomized Treatment Withdrawal Phase for patients re-randomized to apremilast at Week 32 (Table 5).
I begge studier forblev progesteronplasma- koncentrationerne hos de patienter, der fik efavirenz og DMPA, lave i overensstemmelse med undertrykkelsen af ovulationen.
In both studies, plasma progesterone levels for subjects receiving efavirenz and DMPA remained low consistent with suppression of ovulation.
I begge studier førte behandlingen med lumacaftor/ivacaftor til en statistisk signifikant forbedring i ppFEV1 (tabel 3).
In both trials, treatment with lumacaftor/ivacaftor resulted in a statistically significant improvement in ppFEV1 (Table 3).
I begge studier har frekvens, type og sværhedsgrad af bivirkninger observeret hos børn og unge generelt været de samme som observeret hos voksne med undtagelse af infektioner, som blev rapporteret med en højere hyppighed, især hos børn under 3 år.
In both studies, frequency, type and severity of adverse reactions observed in children and adolescents have been generally consistent with those observed in adults, with the exception of infections which were reported at a higher frequency, especially in children below the age of 3 years.
I begge studier havde en tredjedel af patienterne i gennemsnit Sjögrens syndrom; mht. den generelle population blev der observeret en statistisk signifikant forbedring i CFS til fordel for IKERVIS i denne undergruppe af patienter.
In both studies one third of the patients in average had Sjögren’s syndrome; as for the overall population, a statistically significant improvement in CFS in favour of IKERVIS was observed in this subgroup of patients.
I begge studier indgik patienter med aktiv sygdom i en åben behandlingsperiode på maksimalt 6 uger, hvor de behandlede afficerede læsioner med tacrolimussalve to gange daglig, indtil forbedringen havde nået en prædefineret score (Investigator’s Global Assessment [IGA] ≤ 2, dvs. helet, næsten helet eller kun mild sygdom).
In both studies, patients with active disease entered an open-label period (OLP) during which they treated affected lesions with tacrolimus ointment twice daily until improvement had reached a predefined score (Investigator’s Global Assessment [IGA] ≤ 2, i.e. clear, almost clear or mild disease) for a maximum of 6 weeks.
I begge studier medførte behandling med epoetin theta et signifikant hæmoglobinrespons (p <0,001), defineret som en stigning i hæmoglobin på ≥ 2 g/dl uden transfusion, og en signifikant reduktion i transfusionsbehov (p <0,05) sammenlignet med placebo.
In both studies, treatment with epoetin theta resulted in a significant haemoglobin response (p < 0.001), defined as an increase in haemoglobin of ≥ 2 g/dl without transfusion, and a significant reduction in transfusion requirements (p < 0.05) in comparison to placebo.
I begge studier medførte oral og intravenøs topotecan samme symptomlindring hos patienter med recidiverende, sensitiv SCLC i henhold til patienternes egne rapporteringer på en ublindet symptomskala.
Oral and intravenous topotecan were associated with similar symptom palliation in patients with relapsed sensitive SCLC in patient self- reports on an unblinded symptom scale assessment in each of these two studies.
I begge studier nedsatte behandlingen sværhedsgraden af patienternes mest generende baseline VVA-symptom, nedsatte vaginalt pH, nedsatte procentdelen af vaginale parabasale celler fra maturation index (MI) og øgede procentdelen af vaginale overfladeceller fra MI.
In both studies, it decreased the severity of the subject’s most bothersome baseline VVA symptom, decreased vaginal pH, decreased the percentage of vaginal parabasal cells from the maturation index (MI) and increased the percentage of vaginal superficial cells from the MI.
I begge studier opstod de fleste tilfælde af hypertension hos patienter behandlet med Stivarga i løbet af den første behandlingscyklus, og de var lette til moderate i sværhedsgrad (grad 1 og 2: 22,8 % (KRC) og 31,1 % (GIST)).
In both trials, most cases of hypertension in patients treated with Stivarga appeared during the first cycle of treatment and were mild to moderate in severity (Grades 1 and 2: 22.8%, CRC and 31.1%, GIST).
I begge studier opstod de fleste tilfælde af hånd-fod-hudreaktion hos patienter i behandling med Stivarga i løbet af den første behandlingscyklus, og de var lette til moderate i sværhedsgrad (grad 1 og 2: 28,6 % (KRC) og 44,7 % (GIST)).
In both trials, most cases of hand-foot skin reaction in patients treated with Stivarga appeared during the first cycle of treatment and were mild to moderate in severity (Grades 1 and 2: 28.6%, CRC and 44.7%, GIST).
I begge studier resulterede behandling med ambrisentan, uanset dosis i en signifikant forbedring af 6MWD.
In both studies, treatment with ambrisentan resulted in a significant improvement in 6MWD for each dose of ambrisentan.
I begge studier tog patienterne i lenalidomid/ dexamethason-(len/dex)-gruppen 25 mg lenalidomid oralt, én gang dagligt på dag 1 til 21 og en tilsvarende placebokapsel én gang dagligt på dag 22 til 28 i hver 28-dages cyklus.
In both studies, patients in the lenalidomide/dexamethasone (len/dex) group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28- day cycle.
I begge studier var de bronkodilaterende effekter af Incruse sammenlignet med placebo evidente efter den første dag med behandling og blev opretholdt over behandlingsperioderne på 12 uger og 24 uger.
The bronchodilatory effects with Incruse compared with placebo were evident after the first day of treatment in both studies and were maintained over the 12-week and 24-week treatment periods.
I begge studier var den samlede forekomst af hånd-fod-hudreaktion (78,4% (KRC) og 88,2% (GIST)) højere hos Stivargabehandlede patienter af asiatisk herkomst, sammenlignet med andre etniciteter.
In both trials, the overall incidence of hand-foot skin reaction (78.4%, CRC and 88.2%, GIST) was higher in Stivarga-treated Asian patients compared to other ethnicities.
I begge studier var der et klart fald i HbA1c i begge behandlingsgrupper allerede ved den første måling af HbA1c efter behandlingsstart (uge 4 eller 6).
In both studies, decreases in HbA1c were evident in both treatment groups as early as the first post-treatment HbA1c measurement (weeks 4 or 6).
I begge studier var der et signifikant fald af de individuelle serotyper 6B og 19F. I det finske undestudie blev der yderligere set en signifikant reduktion af de individuelle serotyper 14 og 23F, samt af den krydsreaktive serotype 19A i 3-dosis primærvaccinationsprogrammet.
In both studies there were significant decrease of individual serotypes 6B and 19F. In the nested Finnish study, a significant reduction was also observed for individual serotypes 14, 23F and, in the 3 dose primary schedule, for the cross-reactive serotype 19A.
I begge studier var det primære endepunkt andelen af patienter, som opnåede PASI-75 efter uge 16.
In both studies, the primary endpoint was the proportion of patients who achieved PASI-75 at Week 16.
I begge studier var det primære endepunkt for virkning den gennemsnitlige ændring fra baseline af BCVA ved uge 52, og både Eylea 2Q8- og Eylea 2Q4-grupperne viste en statistisk signifikans og var bedre end kontrolgruppen.
In both studies, the primary efficacy endpoint was the mean change from baseline in BCVA at Week 52 and both Eylea 2Q8 and Eylea 2Q4 groups demonstrated statistical significance and were superior to the control group.
I begge studier, hos patienter med AR ved år 2, var donor-specifikke antistoffer, som var et af diagnosekriterierne for antistof-medieret afstødning, til stede hos henholdsvis 6% (2/32, Studie 2)-8% (3/39, Studie 1) og 20% (4/20, Studie 1)- 26% (7/27, Studie 2) i belatacept- og ciclosporin-grupperne ved år 3.
In both studies, in patients with AR by Year 2, donor-specific antibodies, one of the criteria for diagnosis of antibody-mediated rejection, were present in 6% (2/32, Study 2)-8% (3/39, Study 1) and 20% (4/20, Study 1)-26% (7/27, Study 2) in the belatacept and ciclosporin groups by year 3, respectively.
I begge studierne blev patienterne randomiseret i forholdet 2:1 til apremilast 30 mg 2 gange dagligt eller placebo i 16 uger (placebokontrolleret fase) og fra uge 16-32 fik alle patienter apremilast 30 mg to gange dagligt (vedligeholdelsesfase).
In both studies, patients were randomized 2:1 to apremilast 30 mg BID or placebo for 16 weeks (placebo-controlled phase) and from Weeks 16-32, all patients received apremilast 30 mg BID (maintenance phase).
I begge tilfælde bør der indgives et nyt implantat som erstatning.
In both of these circumstances a replacement implant should be administered.
I begge tilfælde bør et erstatningsimplantat.indgives.
In both of these circumstances a replacement implant should be administered.
I begge tilfælde er antallet af VTE’er pr. år mindre end det forventede antal hos kvinder under graviditet eller i post partum-perioden.
In both cases, the number of VTEs per year is fewer than the number expected in women during pregnancy or in the postpartum period.
I begge tilfælde er det vist, at oocyst udskillesen reduceres.
In both cases, the reduction of oocysts excretion has been demonstrated.
I begge tilfælde er vist, at oocyst udskillesen reduceres.
In both cases, the reduction of oocysts excretion has been demonstrated.
I begge tilfælde kan behandling med dapagliflozin genoptages, når patientens tilstand er stabiliseret.
In both cases, treatment with dapagliflozin may be restarted once the patient’s condition has stabilised.
I begge tilfælde kan behandlingen med canagliflozin genoptages, når patientens tilstand er stabil.
In both cases, treatment with canagliflozin may be restarted once the patient’s condition has stabilised.
I begge tilfælde kan behandlingen med dapagliflozin genoptages, når patientens tilstand er stabiliseret.
In both cases, treatment with dapagliflozin may be restarted once the patient’s condition has stabilised.
I begge tilfælde kan behandlingen med empagliflozin genoptages, når patientens tilstand er blevet stabil.
In both cases, treatment with empagliflozin may be restarted once the patient’s condition has stabilised.
I begge tilfælde kan behandlingen med Vokanamet genoptages, når patientens tilstand er stabil.
In both cases, treatment with Vokanamet may be restarted once the patient’s condition has stabilised.
I begge tilfælde måles plasmakoncentrationen af A771726 herefter for første gang.
In either case the A771726 plasmaconcentration is then measured for thefirst time.
I begge tilfælde skal De bruge et nyt plaster på det sædvanlige tidspunkt den følgende dag.
In both cases, on the following day you should use a new patch at the usual time.
I begge tilfælde skal hele pakningen returneres til apoteket.
In both these cases, return the entire pack to the pharmacy.
I begge undersøgelser af injektionsvæsken blev urosymptomerne mindsket væsentligt mere hos de patienter, der fik Abilify, end hos dem, der fik placebo.
In both studies of the solution for injection, patients receiving Abilify had a greater reduction in symptoms of agitation than those receiving placebo.
I begge undersøgelser blev behandlingens virkning hovedsagelig bedømt på, hvor mange patienter der reagerede helt eller delvis positivt på behandlingen.
both studies, the main measure of effectiveness was the number of patients with a complete or partial response to treatment.
I begge undersøgelser blev det også registreret, i hvilken grad virkningen holdt sig i det andet behandlingsår, hvor antallet af injektioner og tidsrummet mellem injektionerne blev tilpasset efter patientens synsevne og forandringerne inde i øjet.
Both studies also looked at the maintenance of the effect in the second year of treatment, during which the number of injections and the time between injections were adjusted depending on the vision and changes within the eye.
I begge undersøgelser blev effekten af en enkelt injektion af Neulasta sammenlignet med flere daglige injektioner af filgrastim under hver af de fire kemoterapicyklusser.
In both studies, the effectiveness of a single injection of Neulasta was compared with multiple daily injections of filgrastim during each of four chemotherapy cycles.
I begge undersøgelser blev Eliquis sammenlignet med enoxaparin (et andet lægemiddel, som anvendes til forebyggelse af blodpropper).
In both studies, Eliquis was compared with enoxaparin (another medicine used to prevent blood clots).
I begge undersøgelser blev Intelence sammenlignet med placebo (en virkningsløs behandling), når det blev indtaget sammen med boosted darunavir (en proteasehæmmer) og mindst to andre lægemidler mod hiv, som blev udvalgt for hver enkelt patient, da de havde de bedste chancer for at nedbringe hiv-niveauet i blodet.
Both studies compared Intelence with placebo (a dummy treatment), when they were taken with boosted darunavir (a protease inhibitor) and at least two other anti-HIV medicines that were chosen for each patient as they had the best chances of reducing the levels of HIV in the blood.